23. The composition of claim 22 wherein the composition further comprises at least 5, 6, 7, 8, 9, or 10 different classes of bacteria chosen from Actinobacteria, Bacteroidia, Bacilli, Clostridia, Erysipelotrichi, Alphaproteobacteria, Betaproteobacteria, Gammaproteobacteria, Mollicutes, and Verrucomicrobiae.

24. The composition of claim 17 or 19 wherein the process further comprises adding a cryoprotectant to the composition.

25. The composition of claim 24 wherein the process further comprises freezing the composition.

26. A composition as described in claim 1, 2, 3, or 4 for use as a therapeutic agent.

27. A composition as described in claim 1, 2, 3, or 4 for use in the treatment of a disease or a pathological or iatrogenic condition of the colon.

28. The composition of claim 28 wherein the disease is a disease or condition characterized by a dysfunctional or pathological composition of colon microbiota.

29. The composition of claim 29 wherein the disease is a *Clostridium difficile* colitis.

30. ~~A method for replacing or supplementing or modifying a subject's colon microbiota, the method comprising:~~

~~administering to the subject~~Use of the composition of claims 1, 2, 3, 4, 16, 17, or 19 in the preparation of a medicament for replacing or supplementing or modifying a subject's colon microbiota.

31. ~~A method for treating a subject, the method comprising:~~

~~administering to a subject in need thereof a~~An effective amount of the composition of claim 1, 2, 3, 4, 16, 17, or 19 for use in therapy.

32. The ~~method~~ use of claim 30 ~~or 31~~, wherein ~~further comprising removal of~~ some, most, or substantially all of the subject's colon, gut or intestinal microbiota have been removed prior to ~~the~~ administration~~ering~~ of said medicament.

33. The ~~method~~ use of claim ~~31~~ 32, wherein the subject has or is at risk for having a colitis.

34. The ~~method~~ use of claim 33 wherein the colitis is an autoimmune colitis.

35. The ~~method~~ use of claim 34 wherein the autoimmune colitis is selected from an inflammatory bowel disease, an ulcerative colitis, a Crohn's disease and an irritable bowel syndrome.

36. The ~~method~~ use of claim 33 wherein the colitis is an infectious colitis.

37. The ~~method~~ use of claim 36 wherein the infectious colitis is selected from a *Clostridium difficile* colitis and an enterohemorrhagic colitis.

38. The ~~method~~ use of claim 37, wherein the *Clostridium difficile* colitis is selected from an acute *Clostridium difficile* colitis, a relapsing *Clostridium difficile* colitis, and a severe *Clostridium difficile* colitis.

39. The ~~method~~ use of claim 37 wherein the enterohemorrhagic colitis is caused by a microbe selected from a *Shigella* spp. and an *E. coli*.

40. The ~~method~~ use of claim 31 wherein the subject has or is at risk for chronic diarrhea or chronic constipation.

41. Use of a composition of any of claims 1 to 29, for the manufacture of a medicament.

42. Use of a composition of any of claims 1 to 29, for the manufacture of a medicament for treating or ameliorating or preventing a disease or a pathological or iatrogenic condition of the colon,